PTC Therapeutics | PTCT - Current Liabilities


PTC Therapeutics reported $923.6M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 305.52M 28.41M Mar/2026
Alnylam Pharmaceuticals USD 1.35B 116.87M Mar/2026
Amgen USD 24.96B 534M Mar/2026
BioCryst Pharmaceuticals USD 195.39M 675K Mar/2026
Biogen USD 3B 350.5M Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Cytokinetics USD 199.18M 3.27M Mar/2026
Daiichi Sankyo JPY 778.55B 77.51B Dec/2025
Enanta Pharmaceuticals USD 44.73M 3.83M Dec/2025
Esperion Therapeutics USD 300.36M 451K Mar/2026
Gilead Sciences USD 9.48B 2.34B Mar/2026
Incyte USD 1.49B 25.52M Mar/2026
Ionis Pharmaceuticals USD 717M 66M Mar/2026
Ironwood Pharmaceuticals USD 236.31M 5.91M Mar/2026
Karyopharm Therapeutics USD 92.06M 4.9M Dec/2025
Novartis USD 31.37B 4.1B Mar/2026
Pfizer USD 34.35B 2.64B Mar/2026
PTC Therapeutics USD 923.6M 44.82M Mar/2026
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Roche Holding CHF 28B 421M Dec/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sarepta Therapeutics USD 499.16M 596.13M Mar/2026
TG Therapeutics USD 187.11M 33.35M Mar/2026
Ultragenyx Pharmaceutical USD 325M 59M Mar/2026
Vertex Pharmaceuticals USD 3.88B 19.4M Mar/2026
Xencor USD 73.46M 22.45M Mar/2026